Jay R. Luly

President, Chief Executive Officer & Director at Enanta Pharmaceuticals, Inc.

Jay R. Luly

Jay R. Luly

President, Chief Executive Officer & Director at Enanta Pharmaceuticals, Inc.

Overview
Career Highlights

Enanta Pharmaceuticals, Inc.

RelSci Relationships

2238

Birthday

1957

Age

64

Relationships
RelSci Relationships are individuals Jay R. Luly likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Executive Chairman at Infectious Disease Research Institute

Relationship likelihood: Strong

Co-Founder at EGS Healthcare Capital Partners LLC

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Former Chief Executive Officer at Valeritas, Inc.

Relationship likelihood: Strong

Co-Founder at BioVentures Investors

Relationship likelihood: Strong

Founder at Avaxia Biologics, Inc.

Relationship likelihood: Strong

Former Chief Medical Officer & Executive Vice President at Cephalon, Inc.

Relationship likelihood: Strong

Chief Financial Officer & Senior Vice President-Finance & Administration at Enanta Pharmaceuticals, Inc.

Relationship likelihood: Strong

Secretary at Enanta Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at LifeMine Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Jay R. Luly
Potential Connections via
Relationship Science
You
Jay R. Luly
President, Chief Executive Officer & Director at Enanta Pharmaceuticals, Inc.
Education
Ph.D. in Synthetic Organic Chemistry

University of California Berkeley National rankings: In a National Research Council analysis of 212 doctoral programs at American universities, 48 Berkeley programs place among the top 10 nationwide. Faculty awards and honors: There are 8 Nobel Laureates, 32 MacArthur Fellows, and 4 Pulitzer Prize winners among the current faculty. History of UC Berkeley: Historical highlights, arranged by topic, following the campus's development — from UC's founding in 1868 to a turn-of-the-century building boom, a research explosion in the 1930s, the Free Speech Movement of the '60s, and Berkeley's key role today in science and technology revolutions. Timeline of discoveries and contributions by UC Berkeley scholars. Traditions of Cal: Who was the Angel of Death? What's with the "Big C" up there in the hills — and why is it sometimes green? Who wears Oski's jolly bear head and size 54 yellow sweater? Tours and webcams: Check out what's happening on Sproul Plaza, the campus's true heart. See stunning live views of the Bay Area from the Lawrence Hall of Science's perch in the Berkeley hills. Chancellor and administration: Information on Chancellor Robert Birgeneau, Executive Vice Chancellor and Provost George W. Breslauer, and how the university is organized. Organizational charts are included. UC System overview and links: On the campuses, laboratories, and medical centers that comprise UC's public educational system, as well as UC's K-12 partnerships, economic impact, and agriculture and environmental resources.

UIC is a major research university offering the cultural, business and entertainment opportunities you can only find in a world-class city. As one of the top 200 research-funded institutions in the world, UIC faculty discover the things that others teach. Choose from 15 academic colleges including the UIC College of Medicine-the largest in the nation-which educates one in six Illinois physicians. With nearly 2,574 instructional faculty members, there is one faculty member to every 11 students, which allows for a more personal learning experience. What's more, 75 percent of tenured faculty members teach undergraduate courses and 83 percent of full-time instructional faculty have earned a PhD or equivalent. But it's not all work and no play at UIC... Our 16,911 undergrads and 10,669 graduate and professional students make up one of the most diverse student bodies in the United States. Whether living in residence halls, near campus or commuting, you'll find there's always something interesting going on, from social events, clubs, sororities and fraternities, to two state-of-the-art fitness centers, and more-not to mention everything Chicago has to offer just minutes away. And at UIC, we take our sports seriously. The UIC Flames compete in 18 NCAA Division 1 sports and have won a total of 38 conference championships. There's a wide range of intramural teams and sports clubs for students to join.

BS

The University of Illinois at Urbana–Champaign is a public research-intensive university in the U.S. state of Illinois. It is the flagship campus of the University of Illinois system. The University of Illinois at Urbana–Champaign is the second oldest public university in the state (after Illinois State University), and is a founding member of the Big Ten Conference. It is considered a Public Ivy and is a member of the Association of American Universities.

Career History
President, Chief Executive Officer & Director
2003 - Current

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Entrepreneur in Residence
2002 - Prior

Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations.

Senior Vice President-Drug Discovery & Pre-Clinical Development
1983 - 1997

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Boards & Committees
Director
Prior

Artesian Therapeutics, Inc. develops and manufactures biopharmaceutical therapeutic products. Its products are used for the treatment of cardiovascular and other life threat diseases. The company was founded by Peter D. Suzdak in March 2002 and is located in Gaithersburg, MD

President, Chief Executive Officer & Director
2003 - ?

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Trustee
Prior

BBRI DOES BASIC BIOMEDICAL RESEARCH DEDICATED TO THE UNDERSTANDING, TREATMENT AND PREVENTION OF HUMAN DISEASES. THE INSTITUTE'S INNOVATIVE RESEARCH HAS YIELDED LANDMARK ADVANCES IN MUSCULAR DYSTROPHIES, CANCER, CARDIOVASULAR DISEASE AND ARTHRITIS.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$5,000 - $10K
2011

BBRI DOES BASIC BIOMEDICAL RESEARCH DEDICATED TO THE UNDERSTANDING, TREATMENT AND PREVENTION OF HUMAN DISEASES. THE INSTITUTE'S INNOVATIVE RESEARCH HAS YIELDED LANDMARK ADVANCES IN MUSCULAR DYSTROPHIES, CANCER, CARDIOVASULAR DISEASE AND ARTHRITIS.

$2,500 - $4,999
2010

BBRI DOES BASIC BIOMEDICAL RESEARCH DEDICATED TO THE UNDERSTANDING, TREATMENT AND PREVENTION OF HUMAN DISEASES. THE INSTITUTE'S INNOVATIVE RESEARCH HAS YIELDED LANDMARK ADVANCES IN MUSCULAR DYSTROPHIES, CANCER, CARDIOVASULAR DISEASE AND ARTHRITIS.

$2,500 - $4,999
2009

BBRI DOES BASIC BIOMEDICAL RESEARCH DEDICATED TO THE UNDERSTANDING, TREATMENT AND PREVENTION OF HUMAN DISEASES. THE INSTITUTE'S INNOVATIVE RESEARCH HAS YIELDED LANDMARK ADVANCES IN MUSCULAR DYSTROPHIES, CANCER, CARDIOVASULAR DISEASE AND ARTHRITIS.

Transactions
Details Hidden

Enanta Pharmaceuticals, Inc. issued USD Common Stock

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jay R. Luly. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jay R. Luly's profile does not indicate a business or promotional relationship of any kind between RelSci and Jay R. Luly.